NRx Pharmaceuticals, Inc. (NRXP) shares are rising more than 31 percent on Thursday morning after the company announced first successful commercial formulation of Zyesami or aviptadil for intravenous use in COVID-19 patients.
The company said the original RLF-100 formulation and manufacturing method had only a few weeks of stability, leaving hospitals unable to stock in pharmacies, and leaving aviptadil out of consideration for national strategic stockpiles.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com